Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Details ASCO Abstracts for Four Novel Apoptosis Cancer Drugs

publication date: May 26, 2023

Ascentage Pharma offered a summary of four abstracts for novel cancer drug candidates that will be presented at the upcoming 2023 ASCO Annual Meeting: a China-approved third-gen Bcr-Abl inhibitor, a Bcl-2 selective inhibitor, an MDM2-p53 inhibitor and a FAK/ALK/ROS1 inhibitor. Ascentage develops novel therapies for cancers, chronic hepatitis B and age-related diseases. The company focuses on candidates that inhibit protein-protein interactions to restore apoptosis. Ascentage claims to be the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital